In agreement, plasma IL-6 levels showed a reduction 26 days following the initiation of ketamine infusions [26] and after 6 esketamine applications [27], and IL-6 levels were associated with a reduction in symptoms of depression [26] but not with the changes in anhedonia scores [27]. The gene discussed is IL6; the disease is depressive symptom measurement.